DNA-PK inhibitors

Patent metadata

Field	Value
Publication number	US-10786512-B2
Application number	US-201916282083-A
Country	US
Kind code	B2
Filing date	Feb 21, 2019
Priority date	Mar 12, 2013
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

First claim

What is claimed is:

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is of formula:

3. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt.

4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A compound of formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , wherein the compound is of formula:

7. The compound of claim 5 , wherein the compound is a pharmaceutically acceptable salt.

8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 5 , or a pharmaceutically acceptable salt thereof.

Assignees

• Vertex Pharma

Inventors

• Maxwell John Patrick
• Charifson Paul S
• Tang Qing
• Ronkin Steven M
• Jackson Katrina Lee
• Pierce Albert Charles
• Lauffer David J
• Li Pan
• Giroux Simon
• Xu Jinwang
• Cottrell Kevin Michael
• Morris Mark A
• Waal Nathan D
• Court John J
• Gu Wenxin
• Deng Hongbo

Classifications

• C07D413/02

  containing two hetero rings · CPC title

• A61K31/5377 Primary

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C07D513/04

  Ortho-condensed systems · CPC title

• C07D498/08 Primary

  Bridged systems · CPC title

• C07D491/08

  Bridged systems · CPC title